Pertuzumab and trastuzumab infusion related cytokine release syndrome in a chemotherapy naive patient with metastatic breast cancer

Abstract
Pertuzumab is a monoclonal antibody that targets and down regulates HER‐2/neu expression in ductal breast tumors. Other HER‐2/neu monoclonal antibodies, particularly trastuzumab, have been implicated to induce infusion related reactions such as cytokine release syndrome (CRS). Here, we report a case of pertuzumab associated CRS prior to infusion of trastuzumab which warranted hospitalization for symptom management.

Source: The Breast Journal - October 13, 2017 Category: Cancer & Oncology Authors: Adonice Khoury, Vikas Parihar, Lillie O'steen, Kartikeya Cherabuddi Tags: CASE REPORT Source Type: research